Podcasts about Biomarker

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.

Studierende der Leibniz Universität Hannover erklärenSmart Dressings, Fischhaut-Implantate und die Zukunft der medizinischen Wundversorgung.

In Folge 366 spricht Prof. Bernhard Hemmer über die Global MS Prevention Initiative und die Frage, wie realistisch MS-Prävention ist. Er erklärt, warum Multiple Sklerose vermutlich schon Jahre vor den ersten Symptomen beginnt, welche Rolle das Epstein-Barr-Virus, Risikofaktoren, MRT-Befunde und Biomarker wie Neurofilamente spielen und warum internationale Zusammenarbeit so entscheidend ist. Außerdem geht es um Studien mit Angehörigen von Menschen mit MS, die Chancen einer EBV-Impfung und die großen Hürden auf dem Weg zu echter Prävention. Das Interview zum Nachlesen findest du auf meinem Blog: https://ms-perspektive.de/366-prof-hemmer Themen der Folge: Was bedeutet MS-Prävention konkret? Welche Rolle spielt das Epstein-Barr-Virus? Wie lassen sich Risikopersonen früher erkennen? Warum sind Kanada und Australien Vorbilder? Welche Meilensteine sind in den nächsten 5–10 Jahren realistisch? Wie können Betroffene und Angehörige informiert bleiben? Ressourcen & Verweise: MS Canada MS Australia EMSP Webseite zum EU Projekt: https://emsp.org/projects/wisdom/ Flyer zur Studie: https://assets.ms-patenprogramm.de/media/documents/2024/11/Predict_Studie.pdf Ansprechpartner für die Studie: Paula Uibel: Paula.Uibel@mri.tum.de Bernhard Hemmer: Bernhard.Hemmer@mri.tum.de Prof. Bernhard Hemmer: Prävention ist bei MS kein einfacher Weg. Aber sie ist ein realistisches Ziel, wenn viele Menschen zusammenarbeiten. Wichtig ist, Hoffnung und Realismus zu verbinden. Es wird nicht die eine schnelle Lösung geben. Aber die Fortschritte der letzten Jahre zeigen, dass wir MS immer besser verstehen. Wer heute mit MS lebt, profitiert bereits von deutlich besseren Therapien als frühere Generationen. Und für kommende Generationen könnte es möglich werden, noch früher anzusetzen. Das Ziel ist klar: MS nicht nur behandeln, sondern eines Tages verhindern. --- Bis bald und mach das Beste aus deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Warum ist die Diagnose von postinfektiösen Erkrankungen bei Kindern so schwierig? Eine Sonderfolge mit Dr. Daniel Vilser.Es ist schwer zu sagen, wie viele Kinder und Jugendliche in Deutschland an postinfektiösen Erkrankungen leiden - ausgelöst durch verschiedene Erreger, nicht nur durch Corona. Schätzungen reichen von 10.000 bis 100.000 Fällen. Das Krankheitsbild ist divers, deshalb sind Diagnose und Therapie nach wie vor schwierig. Obwohl es für Kinder neuerdings ein bundesweites Versorgungsnetzwerk gibt, klagen betroffene Familien weiter über Wartezeiten und Unkenntnis im Gesundheitssystem, und es mangelt an großen Studien. Was weiß man mittlerweile über die Krankheitsmechanismen? Darüber spricht "Synapsen"-Host Korinna Hennig in dieser Sonderfolge mit Dr. Daniel Vilser, der sich während der Pandemie als einer der ersten mit Long Covid bei Kindern beschäftigt hat. Heute ist er Chefarzt der Klinik für Kinder- und Jugendmedizin am AMEOS-Klinikum in Neuburg und leitet dort eine Ambulanz für Betroffene. Er schildert die vergebliche Suche nach einem Biomarker und den langen Weg zur Evidenz bei Medikamenten - und erzählt, warum er seinen Patientinnen und Patienten trotz allem Hoffnung machen will.HINTERGRUNDINFORMATIONENVersorgungsnetz für Postinfektiöse Erkrankungen bei Kindern in Deutschland: https://pednet-lc.de/Daten aus der RECOVER-Studie zu Long Covid bei Kindern und Jugendlichen: https://jamanetwork.com/journals/jama/fullarticle/2822770Studie von Daniel Vilser et al. zu Long Covid-Subtypen: https://www.nature.com/articles/s41467-026-72224-yStudie zu Risikofaktoren für schweres Post Covid bei jungen Patient:innen: https://link.springer.com/article/10.1007/s00431-026-06995-3Alle weiteren Quellen findet ihr im Artikel zur Folge auf der Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHabt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.deHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Warum ist die Diagnose von postinfektiösen Erkrankungen bei Kindern so schwierig? Eine Sonderfolge mit Dr. Daniel Vilser.Es ist schwer zu sagen, wie viele Kinder und Jugendliche in Deutschland an postinfektiösen Erkrankungen leiden - ausgelöst durch verschiedene Erreger, nicht nur durch Corona. Schätzungen reichen von 10.000 bis 100.000 Fällen. Das Krankheitsbild ist divers, deshalb sind Diagnose und Therapie nach wie vor schwierig. Obwohl es für Kinder neuerdings ein bundesweites Versorgungsnetzwerk gibt, klagen betroffene Familien weiter über Wartezeiten und Unkenntnis im Gesundheitssystem, und es mangelt an großen Studien. Was weiß man mittlerweile über die Krankheitsmechanismen? Darüber spricht "Synapsen"-Host Korinna Hennig in dieser Sonderfolge mit Dr. Daniel Vilser, der sich während der Pandemie als einer der ersten mit Long Covid bei Kindern beschäftigt hat. Heute ist er Chefarzt der Klinik für Kinder- und Jugendmedizin am AMEOS-Klinikum in Neuburg und leitet dort eine Ambulanz für Betroffene. Er schildert die vergebliche Suche nach einem Biomarker und den langen Weg zur Evidenz bei Medikamenten - und erzählt, warum er seinen Patientinnen und Patienten trotz allem Hoffnung machen will.HINTERGRUNDINFORMATIONENVersorgungsnetz für Postinfektiöse Erkrankungen bei Kindern in Deutschland: https://pednet-lc.de/Daten aus der RECOVER-Studie zu Long Covid bei Kindern und Jugendlichen: https://jamanetwork.com/journals/jama/fullarticle/2822770Studie von Daniel Vilser et al. zu Long Covid-Subtypen: https://www.nature.com/articles/s41467-026-72224-yStudie zu Risikofaktoren für schweres Post Covid bei jungen Patient:innen: https://link.springer.com/article/10.1007/s00431-026-06995-3Alle weiteren Quellen findet ihr im Artikel zur Folge auf der Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHabt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.deHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Download the transcript here

Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Listen to the podcast here

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Scott Grossman, MD, assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine, discusses emerging research on inter-eye retinal nerve fiber layer (RNFL) asymmetry as a biomarker of prior optic neuritis in pediatric-onset multiple sclerosis (POMS). Drawing from data presented at the 2026 American Academy of Neurology Annual Meeting, Grossman explains how optical coherence tomography (OCT) may help improve diagnostic confidence in pediatric MS by identifying remote optic nerve injury, while also outlining how a 4-micron inter-eye RNFL difference emerged as the optimal threshold in this cohort. The conversation also explores the role of OCT within the updated 2024 McDonald Criteria, the feasibility of integrating OCT into routine neurology practice, challenges surrounding normative pediatric OCT data, and future research directions involving visible light OCT and broader population datasets. Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page.Episode Breakdown: 1:15 – Optic nerve involvement and updated MS diagnostic criteria  3:20 – Pediatric RNFL asymmetry thresholds and interpretation of study findings 5:15 – Clinical implications of OCT biomarkers in pediatric-onset MS  6:40 – Neurology News Network  8:40 – Feasibility of incorporating OCT into neurology and MS practice  10:15 – Future research directions, including normative data and visible light OCT The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Pranav Garimella joins host Catherine Glass to explore why early detection of chronic kidney disease remains challenging. From high-risk populations to emerging plasma and urine biomarkers, this episode examines how earlier diagnosis and improved risk stratification can transform patient outcomes. Timestamps: 00:59 – Challenges of early detection 05:12 – Populations for intensive screening 09:08 – Plasma and urine biomarkers 13:45 – Biomarker-driven risk stratification

Wie funktioniert moderne ambulante Versorgung bei Multipler Sklerose? In dieser Folge spreche ich mit Dr. Oliver Fasold über MS-Schwerpunktpraxen, digitale Medizin und die Chancen von Videosprechstunden. Den Beitrag zum Nachlesen findest du auf meinem Blog: https://ms-perspektive.de/362-ms-praxis Wir sprechen darüber, warum viele Menschen nach der Diagnose zunächst orientierungslos sind, welche Rolle Hausärztinnen und Radiologinnen spielen und warum ein gutes Versorgungsnetzwerk so wichtig ist. Außerdem werfen wir einen Blick in die Zukunft: Können digitale Biomarker, Smartwatches und Videosprechstunden die MS-Behandlung verbessern? Darum geht's in dieser Folge Wie funktioniert eine MS-Schwerpunktpraxis? Warum fühlen sich viele nach der Diagnose orientierungslos? Welche Rolle spielen MRTs und Hausärzt*innen? Was kann digitale Medizin leisten? Wo liegen die Grenzen von Videosprechstunden? Welche Entwicklungen wünscht sich Dr. Fasold für die Zukunft? Erwähnte Themen Serum-Neurofilament-Leichtketten (NFL) GFAP-Biomarker Videosprechstunden Digitale Biomarker BTK-Inhibitoren Arbeitskreis Multiple Sklerose Berlin e.V. Was möchtest du den Hörer:innen mitgeben? Lasst euch dort behandeln, wo ihr euch wohlfühlt und wo eure Bedürfnisse ernst genommen werden. Ein gutes Versorgungsnetzwerk kann helfen, Sicherheit im Alltag mit MS zu gewinnen. Und genau darum geht es letztlich: nicht nur medizinisch gut versorgt zu sein, sondern sich langfristig verstanden und begleitet zu fühlen. Wo findet man dich online und vor Ort? Neurozentrum Tempelhof Neurozentrum Tempelhof | Praxisgemeinschaft für Neurologie LinkedIn --- Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, Michael J. Pishvaian, MD, PhD, sat down to discuss the evolving role of biomarker-directed strategies in gastrointestinal (GI) oncology, as well as the importance of early comprehensive testing to identify molecular drivers and resistance mechanisms when approaching frontline treatment selection and sequencing. Pishvaian serves as director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the National Capital Region.Pishvaian began the discussion by highlighting the shift from a disease-site-specific approach to a molecularly defined paradigm, noting that microsatellite instability–high status and NTRK fusions now dictate therapy regardless of tumor origin. He reviewed the transformational data from the phase 3 HERIZON-GE-01 trial (NCT04276493), positing that zanidatamab (Ziihera) could become the new standard of care for HER2-positive upper GI cancers due to unprecedented survival outcomes. He also emphasized the emergence of Claudin 18.2-directed therapies, noting that data from the phase 2 ILUSTRO study (NCT03505320) demonstrates remarkable progression-free survival when adding zolbetuximab (Vyloy) to mFOLFOX6 and nivolumab (Opdivo) for high-expressing subgroups.The conversation then shifted to colorectal cancer, where Dr. Pishvaian detailed how data from the phase 3 BREAKWATER trial (NCT03845036) has "locked in" a paradigm requiring frontline testing for BRAF V600E mutations to guide the use of encorafenib (Braftovi) plus cetuximab (Erbitux). He also discussed the "care revolution" in KRAS inhibition, spotlighting the significant survival benefits seen with daraxonrasib in pancreatic cancer and the potential for novel allele-specific inhibitors to combat disease resistance.Finally, Pishvaian addressed the practicalities of implementation, noting that testing rates in the community remain low. He advocated for prioritizing testing, including liquid biopsies and ctDNA, at the time of initial diagnosis to ensure no patient is left behind.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Chiropraktik hilft nicht nur bei Rückenschmerzen!

Could neoadjuvant immunotherapy be considered part of the standard of care for patients with mismatch repair deficient (dMMR) colon cancer? Credit available for this activity expires: 5/1/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/practical-community-colorectal-cancer-clinic-aligning-2026a1000dw7?ecd=bdc_podcast_libsyn_mscpedu

Longevity, gesundes Altern und ein aktiv verlängertes Leben stehen im Mittelpunkt dieser Episode des Allianz Gesundheitstalks. Der Auftakt der dreiteiligen Podcast Serie beleuchtet den aktuellen Stand der Altersforschung und zeigt, warum ein langes Leben heute neu gedacht wird: nicht als reines Erreichen hoher Lebensjahre, sondern als Verlängerung gesunder Lebenszeit. Zu Gast ist der Journalist und Bestsellerautor Thomas Schulz (DER SPIEGEL). Auf Basis internationaler Forschung, Einblicke aus dem Silicon Valley und Gesprächen mit führenden Wissenschaftlern erläutert er, wie Künstliche Intelligenz, moderne Medizin und neue Biomarker das Verständnis von Alterungsprozessen grundlegend verändern. Ein zentraler Schwerpunkt liegt auf den biologischen Grundlagen des Alterns, den sogenannten Hallmarks of Aging, sowie auf der Frage, welchen Einfluss Gene, Lebensstil, Bewegung und biologische Fitness tatsächlich auf die Lebenserwartung haben.

In this episode, Dr. Rena Malik welcomes Dr. Rachel Rubin to explore the often-overlooked aspects of women's sexual health, including clitoral anatomy, clitoral adhesions, and the impact of hormones throughout the lifespan. The conversation covers essential topics such as sexual pain, the role of hormones during menopause, and why devices and open communication are vital for pleasurable sex. Listeners will come away with practical insights into understanding their own bodies, advocating for better healthcare, and normalizing conversations around sexual well-being. Want clean plant-based skincare: Use code RENA for 20% off at https://www.basedbodyworks.comSave 20% Off Honeylove by going to http://honeylove.com/RENA #honeylovepod Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00:00 Introduction00:02:31 Why Couples Need Better Sexual Health Care00:05:29 The Clitoris and the Anatomy Most Doctors Never Learn00:06:56 Clitoral Adhesions, Pleasure, and Painful Missed Diagnoses00:12:33 How Menopause Changes the Labia and Genital Tissue00:22:32 Sex Education, Masturbation, Shame, and Communication00:29:30 Vaginal Hormones, Menopause, and Painful Sex00:43:16 The Vulvar Vestibule and Hidden Causes of Sexual Pain00:48:28 Birth Control, Hormones, and Sexual Function01:25:08 Sexual Health as a Biomarker of Overall Health01:28:41 Final Takeaways and Closing Reflections Stay connected with Dr. Rachel Rubin on social media for daily insights and updates. Don't miss out—follow her now and check out these links! INSTAGRAM - https://www.instagram.com/drrachelrubin/?hl=en FACEBOOK - https://web.facebook.com/DrRachelRubin/?_rdc=1&_rdr# YOUTUBE - https://www.youtube.com/@DrRachelRubin X - https://x.com/drrachelrubin WEBSITE - https://www.rachelrubinmd.com/ Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Alzheimer's Association released a Special Report that updates dementia and dementia care information. I have on;y read about 1/3 of the info so far, so I expect I'll have a lot more to share over the nexrt several weeks. The industry is getting better at discovering, diagnosing, and managing dementia. I tried to get a link to the report, but I can't find it. The title is "2026 Alzheimer's Disease Facts and Figures". There is a ton of info at the Alzheimer's Association website website https://www.alz.org/ Check out the "About" and 'Research" tabs, and then schedule with me to protect your family, assets and choices when extended care is needed at home, in a family member's home or in a facility/community setting Schedule here

In 1969, Harvard pathologist Kilmer McCully discovered elevated homocysteine causes arterial damage and heart disease. He was forced out of Harvard. The Framingham Heart Study confirmed him. Then the AHA buried it anyway.CHAPTERS:00:00 - McCully discovery and suppression01:20 - Part 1: What homocysteine does to arteries (6 mechanisms)03:25 - Part 2: The evidence they ignored03:40 - Every 5 umol/L: 20-30% higher CAD risk, 60% stroke risk04:50 - Alzheimers risk +48% (meta-analysis, 7,474 subjects)06:10 - Part 3: Why it was abandoned (VISP, NORVIT, HOPE-2)07:50 - Cochrane: B vitamins reduced stroke 10%08:20 - CSPPT: folic acid reduced stroke 21% to 73%09:10 - Part 4: Your brain on homocysteine09:25 - VITACOG: brain atrophy 30% slower, 53% in high-Hcy group10:05 - PNAS 2013: 7x less hippocampal atrophy11:00 - Part 5: What to do11:10 - Test fasting homocysteine: target under 8-10 umol11:40 - Methylfolate, methylcobalamin, P5PREFERENCES:Homocysteine CVD Risk 2025: PMC12564181VITACOG Trial (PLoS ONE, 2010): PMC2935890VITACOG 2025 Metabolomics: PubMed 40684250Homocysteine Alzheimers Risk: PMC12280720Cochrane B Vitamins Stroke: CochraneCSPPT Folic Acid: ACCJAMA 2010 Meta-Analysis: JAMAHOST: Dr. Robert Lufkin MD | robertlufkinmd.com⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every Tuesday & Thursday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/

Are you ready to stop guessing about your health and start getting answers? In this episode, Dana Irvine, FDNP, sits down with Kristy Berry, CEO of Cenegenics, to unpack what performance aging actually looks like for women — and why the conventional healthcare model is failing us. Together, they dig into the power of comprehensive biomarker testing, personalized health protocols, and the functional, root-cause approach to navigating menopause, hormone imbalance, and long-term vitality.Kristy shares how Cenegenics uses over 270 blood biomarkers alongside cognitive and physical assessments to build truly individualized health strategies — moving far beyond the one-size-fits-all advice most women have been handed for decades. You'll hear why continuous monitoring matters, how lifestyle factors like sleep, nutrition, and stress are non-negotiable foundations, and why hormones and peptides — while powerful tools — should support a solid wellness framework, not replace one.If you've ever felt dismissed by your doctor, confused by conflicting hormone health advice, or simply ready to take a proactive, empowered approach to aging well, this episode is your roadmap.Kristy Berry is the CEO of Cenegenics, the world's largest and most experienced performance health and age management medicine practice, with 20 U.S. locations and 8 international centers. Since joining the executive team in 2021, Kristy has led the transformation of Cenegenics from a disease-treatment model to a proactive, preventive approach that helps individuals achieve peak cognitive and physical health at every stage of life. With a background in nursing and healthcare management, Kristy is a passionate advocate for personalized medicine, comprehensive biomarker testing, and empowering women to take full ownership of their health journey.

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications

In dieser Folge spreche ich mit Robin Sorg (Aware Health) darüber, wie präventive Bluttests und Biomarker dir helfen können, Training, Regeneration und Gesundheit besser zu verstehen – ohne Biohacking-Hype, dafür mit konkreter Praxis: testen – handeln – testen.Wir klären u. a.:Warum Normbereich nicht automatisch optimal (für Sport) bedeutetWeshalb ein einzelner Wert selten reicht (Beispiel Ferritin + Entzündungsmarker)Warum „mehr Supplements“ nicht immer besser ist – besonders bei Vitamin DWieso der Omega-3-Index für Ausdauersportler unterschätzt istWie oft Testen sinnvoll ist (Daumenregeln für ambitionierte Sportler vs. Freizeit)Was passiert, wenn Werte stark auffällig sind (Einordnung, nächste Schritte)Wie Aware Blutdiagnostik alltagstauglich macht – inkl. Standorten und dm-PilotLinks & Infos (WERBUNG):Aware Health: www.aware.app/deSport-Paket / passende Pakete: www.aware.app/de/sport-bluttestStandorte: www.aware.app/de/standorteHinweis: Die Inhalte dienen der Information und ersetzen keine ärztliche Beratung oder Diagnose. Bei Beschwerden oder Unsicherheit bitte medizinisch abklären lassen.*WerbesendungAlle aktuellen Partner findest du hier:NordVPN mit verschlüsselter Verbindung und blockiert schädliche Seiten & Tracker.Exklusiv: Großer Rabatt auf das 2-Jahrespaket + 4 Extra-Monate gratis.

Dr. Michel G. Khouri reviews a landmark study examining patients with AL amyloidosis who achieved a complete cardiac biomarker response, highlighting profound improvements in cardiac structure, function, and long-term survival that rival the general population. The discussion underscores the transformative impact of early diagnosis and modern plasma cell–directed therapies, while reminding clinicians that ongoing multidisciplinary cardiac care remains essential even after sustained cardiac remission.

Galectin-3, perhaps a word you have never heard of, is a biomarker that plays a powerful role in inflammation, immune function, cancer progression, and even treatment response.  But shining a light on the "often overlooked" tools is why you are here, and why we interviewed Ruby Tischoff, a Functional Diagnostic Nutrition Practitioner with 25 years of experience in integrative medicine and nutraceutical science. Tune in to uncover valuable insights into targeting testing and how lifestyle factors (toxic exposures, chronic stress, etc.) can elevate galectin-3. And since we are women of solutions, of course, we included steps that may help bring your levels back into balance. One of the main ones Ruby suggests (and so do we!) is Modified Citrus Pectin. Click here to read our blog post on how it stops cancer. You can buy it in powder and capsule form.  This episode is a fascinating one, make sure to bring your notepad!

Featuring an interview with Dr Seth Wander, including the following topics: Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00) Potential role of thymidine kinase testing in monitoring response to therapy (4:56) Interpretation of next-generation sequencing testing; use of targeted therapy (10:59) Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19) Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07) Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15) Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26) Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10) Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31) Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36) Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59) CME information and select publications

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics: Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00) Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21) Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56) Appropriate timing for assessment of ESR1 and PI3K pathway alterations (17:34) Evolving guidelines for routine biomarker evaluation (21:37) Implications of precision oncology clinical trials for future biomarker utility (25:07) Summary, key questions, future directions (33:09) CME information and select publications  

Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer. CME information and select publications here.

What if everything you're doing to stay healthy—your diet, your supplements, your exercise routine—is only part of the story? What if the real question is whether your body is actually absorbing, using, and benefiting at the cellular level? In this powerful solo episode, Dr. Gillian Lockitch invites you to rethink how you measure wellness and healthy aging by introducing a biomarker that is both completely personal and scientifically valid: your antioxidant protection score.Drawing from her background as a physician and specialist medical biochemist, as well as a life-changing personal health scare, Dr. Lockitch explains the invisible but relentless process of oxidative stress—the cellular damage caused by free radicals that accumulates over time and contributes to aging and chronic disease. Through a vivid and emotional story of her sudden diagnosis of myopic macular degeneration, she brings home the reality that aging is not just about time passing, but about what is happening inside your body every single day. This episode goes beyond theory to illuminate the science of antioxidants as your body's essential defense system. You will learn how endogenous antioxidants produced within your cells work in partnership with dietary antioxidants like carotenoids, and why this balance is critical for protecting your brain, eyes, heart, skin, and overall vitality. Dr. Lockitch also explains why nutrient intake alone is not enough—what truly matters is bioavailability, absorption, and delivery to target tissues.Most importantly, this conversation introduces a breakthrough in personalized health: the ability to measure your antioxidant status quickly, non-invasively, and in real time. By tracking carotenoid levels in your skin, with the new Prysm io, you gain a window into your body's internal resilience against oxidative stress. This transforms your approach from guessing and hoping to knowing and acting. If you've ever wondered whether your healthy lifestyle is truly making a difference, this episode will shift your perspective. It is both a call to awareness and a message of empowerment: when you understand what is happening inside your body, you gain the ability to change it—and to take control of how you age, from the inside out.  Episode Timeline: 00:00 – Welcome and introduction  Dr. Gillian introduces the episode and poses the powerful question: do you know your antioxidant score?  01:10 – Why antioxidant protection matters  Explores the gap between healthy habits and measurable protection against oxidative stress.  03:30 – A personal turning point  Dr. Gillian shares her diagnosis of myopic macular degeneration and the urgent treatment that followed.  06:10 – Lessons from the AREDS study  How targeted nutrients support eye health and why prevention is more powerful than treatment.  08:20 – Measuring what matters  Introduction to antioxidant scanning and the surprising results from early testing.  10:30 – Understanding oxidative stress  Clear explanation of free radicals, cellular damage, and environmental contributors.  13:00 – Internal vs dietary antioxidants  How your body's own defense systems work alongside nutrients from food and supplements.  15:10 – The role of carotenoids in healthy aging  How these plant compounds support the eyes, brain, heart, and skin.  17:00 – Introducing the Prysm iO device  How this non-invasive technology measures antioxidant levels in seconds.  18:30 – From guessing to knowing  Why tracking your antioxidant score empowers better aging decisions.  19:30 – Final thoughts and invitation  Call to action to measure, monitor, and take control of your biological aging.  Connect with Dr. Gillian Lockitch Download your Guide to Nature's Colouful Antioxidants Connect with Dr. Gillian Lockitch at askdrgill@gmail.com to request a  zoom call to demo the Prysm io: Email Subject: Prysm Podcast Join the Growing Older Living Younger Facebook Community here  Share the Growing Older Living Younger podcast link for anyone you care about and invite them to subscribe  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients. Presenters: Ann Marie Siney, RN, MSN, ANP-BC Division of Hematology/Oncology UCLA Health Santa Monica, California Kathleen Boyle, DScPAS, PA-C  Gastrointestinal Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts Link to full program: https://bit.ly/4spkxiC Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Why haven't we cured cancer yet? A Genentech scientist explains the real reason.In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Bob Liu, Senior Principal Scientist at Genentech Roche, to unpack one of the most important and misunderstood questions in modern medicine.This is a rigorous, scientifically grounded conversation on cancer biology, immunotherapy, and the real constraints shaping oncology drug development today.Dr. Liu brings over a decade of experience across antibody drug conjugates (ADCs), bispecific antibodies, and CAR-T therapies, offering a rare, insider perspective on why a universal cure remains elusive and where meaningful progress is actually being made.Thanks to our Founding Sponsor: LEUCENTRA: Helping teams evaluate, implement, and get real value from IT solutions that support innovation, not slow it down. https://leucentra.com/ What You'll LearnWhy cancer is not one disease, but more than 200 biologically distinct conditionsWhat “curing cancer” actually means in clinical oncologyHow immunotherapies like checkpoint inhibitors and CAR-T are changing outcomesThe biological limits of eliminating every cancer cellHow tumors evade immune detection and adapt over timeWhy only about 20% of patients respond to immuno-oncology therapiesThe role of biomarkers, molecular profiling, and precision medicineWhy early detection remains one of the biggest unsolved challengesThe economic and regulatory pressures shaping next-generation therapiesKey InsightCancer is not simply something to eliminate.It is a dynamic, adaptive system evolving within the human body. The future of oncology is not just eradication, but control, personalization, and intelligent engagement of the immune system.Notable Quotes“Cancer is a collection of more than 200 diseases, each requiring its own specific approach.”“The cure for some cancers is within reach, but for many others, early detection remains the critical challenge.”“Our immune system is constantly surveilling. The key is learning how to harness it effectively.”Timestamps00:00 – Introduction02:42 – Bob's passion - AACR04:28 – Why we haven't cured cancer07:09 – Defining a cancer cure10:26 – Cancer classification and molecular signatures14:16 – Methylation profiling in diagnosis17:22 – Patient resources and navigation21:14 – FDA shifts toward randomized trials for CAR-T24:15 – Cost and access challenges26:33 – Cancer vs cardiovascular disease progress33:39 – The challenge of early detection37:48 – Biomarker limitations39:14 – Immune system dynamics in cancer45:19 – Bioanalytical challenges in modern therapies51:08 – Progress and future outlookAbout the GuestDr. Bob Liu is a Senior Principal Scientist at Genentech Roche specializing in bioanalytical sciences and immunogenicity assessment for advanced oncology therapies, including T-cell bispecifics and CAR-T.Resources & LinksFDA to tighten approval requirements for CAR-T therapieshttps://www.raps.org/news-and-articles/news-articles/2025/12/fda-to-tighten-approval-requirements-for-car-t-celAmerican Association for Cancer Research (AACR)https://www.aacr.org/National Cancer Institute – Molecular diagnostics and biomarkershttps://www.cancer.gov/about-cancer/diagnosis-staging/diagnosisPattern recognition technologies in diagnosticshttps://toby.healthConnectDr. Bob Liuhttps://www.linkedin.com/in/bob-liu-42b8b278/Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/Final ThoughtThe path to curing cancer is not a single breakthrough. It is a long, complex progression of scientific advances, better diagnostics, and deeper biological understanding.The progress is real.But the work is far from finished.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

What does the future of medicine actually look like?In this episode we sit down with Dr. Rhet Langley, MD and Co-founder of Thrive Medicine Clinic to talk about the evolution of healthcare, from traditional hospital medicine, to modern data-driven longevity clinics.Dr. Langley shares how his experience in anesthesia, pain medicine, and military service led him to rethink the way medicine approaches health. Instead of waiting for disease, his clinic focuses on biomarkers, metabolic health, and proactive diagnostics to help patients transform their health long before problems arise.We discuss:• Why many physicians themselves struggle with health • The shift from reactive medicine to preventative longevity care • Biomarker-driven diagnostics and metabolic testing • The real business challenges of building a medical practice • VO₂ max, metabolic flexibility, and longevity data • Why lifestyle foundations matter more than “biohacks” • How AI may transform patient care and data management • The importance of mental health and human connection in medicineIf you're interested in longevity, functional medicine, healthcare entrepreneurship, or the future of medicine, this episode is packed with insights.

In this episode of the Oncology Brothers podcast, we were joined by two international experts — Professor Gary Tse, a pathologist from the Chinese University of Hong Kong, and Dr. Carlos Barrios, a medical oncologist from Brazil — to unpack the evolving landscape of HER2 testing in breast cancer. What was once a binary positive or negative classification has now expanded to include HER2-low and HER2-ultra-low, opening the door to new treatment options for the majority of breast cancer patients. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: How HER2 classification has evolved from a binary result to a continuous spectrum including HER2-low and HER2-ultra-low, driven by the efficacy of antibody drug conjugates like T-DXd Pre-analytical challenges in metastatic settings including tumor heterogeneity The role of IHC, ISH, NGS, and liquid biopsy in HER2 assessment, and how each tool fits into clinical practice. The importance of multidisciplinary collaboration between pathologists and oncologists to ensure accurate interpretation and optimal treatment selection. Join us for this expert discussion on one of the most clinically impactful topics in breast oncology today. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #HER2, #BreastCancer, #BiomarkerTesting, #PrecisionOncology, #OncologyBrothers

Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice. Presenters: Sara Traverso, MMS, PA-C  Physician Assistant Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center Genitourinary Oncology Chicago, Illinois Brenda Martone, MSN, ANP-BC, AOCNP Nurse Practitioner Northwestern Medicine Chicago, Illinois Link to full program: https://bit.ly/3PB4ZJR Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Your erectile function is literally your body's check engine light—and you're probably ignoring it. If you're a man who tracks his HRV, obsesses over his sleep data, and monitors his testosterone but has no idea what's actually happening with his erectile health, this episode will change everything. Learn why declining erectile function isn't just about aging, how it connects to cardiovascular disease and metabolic health, and what optimal erectile fitness actually looks like versus just "good enough for sex." Whether you're in your 30s noticing subtle changes or in your 40s wondering if what you're experiencing is normal, this episode reveals what your body is trying to tell you before standard medical tests catch it. Discover the difference between maintenance and optimization when it comes to sexual performance. Your dick might be trying to save your life—and you're not even paying attention.   Get the FirmTech cock ring at https://myfirmtech.com/ and use code Naked15 to get 15% off your order. (They are not a sponsor- I just KNOW these devices will help you in bed, and in your overall health).  

In this episode of The Dairy Nutrition Blackbelt Podcast, celebrating International Women's Day, Dr. Megan Abeyta from GPS Dairy Consulting breaks down the physiological and metabolic costs of stress, inflammation, and leaky gut in dairy cattle. She explains how heat stress, acidosis, and management practices influence immune activation and productivity losses. Learn how to use practical indicators like rumination data to identify and reduce risk on-farm. Listen now on all major platforms!"Leaky gut occurs when the gut lining is compromised, allowing harmful substances like endotoxins into the bloodstream."Meet the guest: Dr. Megan Abeyta earned her bachelor's and Ph.D. in Animal Sciences from Iowa State University, focusing her doctoral research on the impact of stress, hindgut acidosis, and leaky gut on dairy cow health and productivity. Now an Independent Dairy Nutrition and Management Consultant with GPS Dairy Consulting, she brings a science-based, practical approach to farm management.Liked this one? Don't stop now — Here's what we think you'll love!What will you learn: (00:00) Highlight(01:21) Introduction(02:32) Leaky gut causes(03:47) Inflammation and energy(06:01) Biomarker indicators(08:38) Identifying farm stressors(10:04) Diet-energy balance(12:10) Closing thoughtsThe Dairy Nutrition Blackbelt Podcast is trusted and supported by the innovative companies:* Vetagro* Barentz* Fortiva* Adisseo* Kemin- DietForge- Virtus Nutrition

What does over 18 months of precision medicine actually look like in practice? In this episode of the Optispan Success Story Series, Dr. Matt Kaeberlein sits down with Carlos Pinto, a tech executive and early Optispan client, to trace his longitudinal health journey from metabolic warning signs to measurable, sustained transformation. Carlos shares how a decade of overlooked biomarkers, a post-pandemic health decline, and a single panic attack became the catalyst for a data-driven approach to his own biology. Together, he and Dr. Kaeberlein review real DEXA, lipid, metabolic, and environmental biomarker data, unpacking what moved the needle, what didn't, and why the answer was rarely simple. This conversation is a candid look at what it means to become your own best health advocate, not through quick fixes, but through personalized, longitudinal learning.Timestamps:0:00 – Cold open & highlights0:50 – Welcome & Carlos's background in tech leadership2:15 – How career ambition displaced health in his 20s and 30s3:39 – A panic attack as the turning point: connecting mental and physical health4:24 – A previous medical wellness program: what worked and what was missing6:34 – Arriving at OptiSpan: intention, mindset, and expectations7:15 – Gateway Day: comprehensive baseline testing and initial surprises8:51 – Early metabolic lessons: CGM data, glucose spikes, and dawn effect11:32 – Confronting white coat hypertension with 78 data points13:28 – How stress, sleep, and nutrition interact to drive metabolic dysfunction15:44 – Personal experimentation as methodology: berberine, time-restricted eating, and fish17:09 – Mercury toxicity from fish consumption: a case study in biomarker surveillance18:33 – Stress management protocols: walking, meditation, and measurable outcomes19:49 – Statin introduction: the role of medication as a tool, not a failure20:27 – DEXA results: visceral fat reduction, body fat loss, and lean mass gain24:17 – Lipid profile transformation: ApoB from ~115 to 70, LDL from 160 to 7425:57 – A1C trajectory and the complexity of glucose optimization30:01 – Reframing medication: proactive use vs. reactive disease management31:29 – Mercury biomarker deep dive: from 2.4 to 16 and back to 232:21 – Goals for the future: sustainability, muscle retention, and mental clarity36:30 – Lineage biological age algorithm: from mortality risk of 54 to 5239:27 – Closing reflections: health as a lifelong trajectory, not a program

The surgeon who spent 12 to14 hours a day in the operating room developed diabetes, uncontrolled high blood pressure, and an autoimmune disease that was eating away at his skull and it forced him to confront what medical school never taught him about actually staying healthy. I sat down with Dr. Darshan Shah, board-certified surgeon, founder of Next Health (one of the largest longevity clinic networks in America), and a doctor who had to reverse his own chronic disease to understand the massive gap between Western medicine and the science of health. We explore why surgeons and physicians become some of the sickest people in healthcare, how functional medicine differs from what you learn in medical school, why biomarker testing matters more than your doctor's "you're fine" assessment, and what root cause medicine actually looks like in practice. Dr. Shah also breaks down the AI revolution happening in cardiovascular imaging with Cleerly scans, how his new AI health dashboard reads your bloodwork and medical records to give you proactive guidance, why Yamanaka factors could regenerate damaged nerves in the brain, and what the future of personalized, preventive medicine looks like when you combine AI with real biological data. Reduce your risk of Alzheimer's with my science-backed protocol for women 30+: https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ TOPICS DISCUSSED 00:00 Intro: The surgeon who developed the diseases he was treating 01:17 From trauma surgeon to longevity doctor: Dr. Shah's journey 04:18 Autoimmune disease, diabetes, and high blood pressure in a surgeon 10:30 Western medicine vs. the science of health 18:45 Why doctors don't learn prevention in medical school 35:20 Next Health clinics and democratizing longevity medicine 52:40 Biomarker testing and why "your labs are normal" is dangerous 01:03:52 AI health dashboard: uploading bloodwork and getting proactive guidance 01:06:45 Cleerly scans and reversing cardiovascular disease with AI imaging 01:10:08 Yamanaka factors, nerve regeneration, and the future of brain health _______ Thank you to our sponsors Function Health: https://www.functionhealth.com/louisanicola Timeline Mitopure: http://timeline.com/NEURO Ka'Chava: https://kachava.com and use code NEURO for 15% off your first order Wayfair: https://www.wayfair.com/ Fenix: https://www.fenixhealthscience.com/ Arey: https://arey.com/ and use code NEURO _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices

Despite major advances in our understanding of the biology of mental health disorders,  there's no blood test or brain scan that will confirm if you have depression, anxiety, PTSD, or any other psychiatric illness.  And yet, the American Psychiatric Association recently announced that it will be including biomarkers for mental conditions in the next edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM), which guides diagnosis and treatment of mental illness. So how close are we to pinpointing the biological markers of mental illness, and what does that mean for diagnosis? It's complicated.  Host Flora Lichtman untangles some of this science with psychiatry researcher John Krystal. Guest: Dr. John Krystal is a professor of psychiatry, neuroscience, and psychology at the Yale School of Medicine. Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Dr. Mena Farag joins Dr. Eduardo de Pablo-Fernández to discuss how proenkephalin and other biomarkers can help monitor the earliest stages of Huntington's disease decades before the onset of motor symptoms. Read the article.

In today's episode, the discussion features Adam Fox, MD, an assistant professor in the Department of Medicine at the College of Medicine at the Medical University of South Carolina in Charleston, and Cynthia A. Schandl, MD, PhD, medical director of clinical laboratories and director of the Division of Clinical Pathology in the College of Medicine at the Medical University of South Carolina, who examined the expanding role of biomarker testing and genomic profiling in non–small cell lung cancer (NSCLC) across disease stages

Show notes: (0:00) Intro (0:49) Dr. Shah's background and personal health crisis (4:55) The most important biomarkers: hs-CRP, A1C, ApoB (7:46) How to track inflammation and metabolic health (13:00) Home tools: bioimpedance scale, grip strength meter (21:09) Nutrition basics: just cut ultra-processed foods (27:09) Hidden toxins in your air, water, and skincare (34:37) Longevity circuit: sauna, cryotherapy, hyperbaric oxygen (38:11) Therapeutic plasma exchange and next-gen biohacking (40:01) Dr. Shah's top 3 health tips anyone can start today (41:18) Where to find Dr. Shah (42:11) Outro Who is Dr. Darshan Shah?   Darshan Shah, MD is a health and wellness specialist, well-known, board-certified surgeon, published author, tech entrepreneur, and founder and CEO of Beautologie and Next Health. As an expert on all body systems, he has performed over 10,000 surgical procedures, including trauma surgery, general surgery and plastic/reconstructive procedures. As a health and wellness specialist, he has advised thousands of patients on how to optimize their well-being and extend their lifespan, culminating in the creation of Next Health, the first health optimization and longevity center to offer life-extending and enhancing technology and treatments in a beautiful, welcoming environment.   Connect with Dr. Shah Website: https://www.drshah.com/ LinkedIn: https://www.linkedin.com/in/darshanshahmd IG: https://www.instagram.com/darshanshahmd/   Grab your free Biomarker guide: https://www.drshah.com/biomarkers   Tune in: https://www.drshah.com/extend Links and Resources: Peak Performance Life Peak Performance on Facebook Peak Performance on Instagram